STAT3 is a genetic modifier of TGF-beta induced EMT in KRAS mutant pancreatic cancer

por D’Amico, Stephen, Kirillov, Varvara, Petrenko, Oleksi, Reich, Nancy C.
Publicado 2023

STAT3 is a master regulator of epithelial identity and KRAS-driven tumorigenesis

por D'Amico, Stephen, Shi, Jiaqi, Martin, Benjamin L., Crawford, Howard C., Petrenko, Oleksi, Reich, Nancy C.
Publicado 2018

IL-6 promotes MYC-induced B cell lymphomagenesis independent of STAT3

por Petrenko, Oleksi, Li, Jinyu, Cimica, Velasco, Mena-Taboada, Patricio, Shin, Ha Youn, D’Amico, Stephen, Reich, Nancy C.
Publicado 2021

KRAS drives immune evasion in a genetic model of pancreatic cancer

por Ischenko, Irene, D’Amico, Stephen, Rao, Manisha, Li, Jinyu, Hayman, Michael J., Powers, Scott, Petrenko, Oleksi, Reich, Nancy C.
Publicado 2021

PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury

por Hammond, Flora M., Alexander, David N., Cutler, Andrew J., D’Amico, Stephen, Doody, Rachelle S., Sauve, William, Zorowitz, Richard D., Davis, Charles S., Shin, Paul, Ledon, Fred, Yonan, Charles, Formella, Andrea E., Siffert, Joao
Publicado 2016

Erratum to: PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury

por Hammond, Flora M., Alexander, David N., Cutler, Andrew J., D’Amico, Stephen, Doody, Rachelle S., Sauve, William, Zorowitz, Richard D., Davis, Charles S., Shin, Paul, Ledon, Fred, Yonan, Charles, Formella, Andrea E., Siffert, Joao
Publicado 2016